GE Healthcare Life Sciences, Sigma-Aldrich License CRISPR/Cas9 Patents
Friday, December 12, 2014
The Broad Institute of MIT and Harvard signed non-exclusive license agreements granting access to its intellectual property relating to the CRISPR/Cas9 gene engineering system for research purposes to GE Healthcare Life Sciences and Sigma-Aldrich, the companies said separately today.
The IP license signed with GE Healthcare Life Sciences includes the first granted patent for the use of CRISPR technology in eukaryotic cells. U.S. Patent No. 8,697,359 was assigned to the Broad Institute and MIT based on work first described in a paper published January 3, 2013, in Science. The paper’s senior author was the listed inventor on the patent, Feng Zhang, Ph.D., a Broad Institute core member.